According to CVS Health, GLP-1 medications can achieve a break-even point for employers and other health plan sponsors if they are priced below $350 per month.
Savings from decreased utilization of emergency room visits and hospitalizations can adequately balance out the expenses of the medications, as noted by CVS Health. The analysis looked at patients newly taking popular GLP-1 medicines from Eli Lilly and Novo Nordisk, comparing them to similar patients not taking the drugs.
The medicines included Mounjaro and Ozempic for diabetes alongside Zepbound and Wegovy for obesity. The analysis covered periods of up to three years, with patients starting treatment between 2023 and 2025.
Corporate Coverage Cuts
As corporations and various health plan sponsors attempt to lower premiums—which are projected to rise by more than 9% in 2027—obesity coverage for GLP-1 drugs is declining. About 14% of companies have already dropped or plan to drop the drugs in 2027.
Zepbound and Wegovy can cost about $299 and $349 for cash-pay customers. A 2025 analysis conducted by the Employee Benefit Research Institute indicated that employers and other health plan sponsors shell out monthly costs ranging from $617 to $766 for these pharmaceuticals. CVS declined to comment on the average prices paid.

“I hope that we can reach that price sooner rather than later,” Dr. Amy Compton-Phillips, chief medical officer at CVS Health, said in an interview ahead of the HLTH USA conference in Las Vegas.
Medical Cost Offsets
GLP-1 use for obesity, diabetes or other conditions was associated with 10% to 12% lower emergency room visits in the first and second year of use. During the research, the organization reviewed files for 60,000 individuals during year one and 20,000 individuals during year two.
An evaluation of data concerning 4,000 individuals maintaining drug usage past the three-year mark demonstrated a 34% to 42% reduction in hospital admissions. Plan sponsors saved $9,400 per person on medical bills, but spent $13,300 more on prescriptions, adding costs of $3,900 per person.

“An older person with diabetes is going to have a higher risk for hospitalization than a younger person who is obese without diabetes,” Compton-Phillips said.
“The higher-risk the person is, the quicker you get to a return on investment,” Dr. Amy Compton-Phillips, chief medical officer at CVS Health, said.
Common Questions on Drug Prices
What did the government pay for GLP-1 drugs?
Under an agreement reached last year, the US government partnered with Lilly and Novo on an 18-month pilot program—evaluating cost-effectiveness for Medicare beneficiaries with disabilities or aged 65 and older—where they agreed to disburse $245 monthly for injectable GLP-1 weight-loss medications.
How many employers are dropping coverage?
A survey fielded by the consultant WTW found that 53% of employers still cover the weight-loss medications, down from 57% a year ago. Among companies that still cover GLP-1s, 30% are considering eliminating coverage, WTW said.
Worth a look